Impact of diabetes mellitus on the outcomes of subjects with hypertrophic cardiomyopathy: A nationwide cohort study

•The clinical impact of ageing-related diseases such as diabetes is becoming increasingly important in HCM.•A nationwide cohort of 9,883 subjects with HCM.•Diabetes is associated with 3.5-fold higher risk of end-stage renal failure in HCM.•Diabetes is associated with 15% higher risk of heart failure...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes research and clinical practice 2022-04, Vol.186, p.109838-109838, Article 109838
Main Authors: Lee, Hyun-Jung, Kim, Hyung-Kwan, Kim, Bong-Seong, Han, Kyung-Do, Rhee, Tae-Min, Park, Jun-Bean, Lee, Heesun, Lee, Seung-Pyo, Kim, Yong-Jin
Format: Article
Language:English
Subjects:
Aged
Atrial Fibrillation - complications
Cardiomyopathy, Hypertrophic - complications
Cardiomyopathy, Hypertrophic - epidemiology
Cohort Studies
Diabetes Complications
Diabetes mellitus
Diabetes Mellitus - epidemiology
Diabetic Cardiomyopathies
Female
Heart failure
Heart Failure - etiology
Humans
Hypertrophic cardiomyopathy
Kidney Failure, Chronic - complications
Male
Middle Aged
Outcomes
Risk Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•The clinical impact of ageing-related diseases such as diabetes is becoming increasingly important in HCM.•A nationwide cohort of 9,883 subjects with HCM.•Diabetes is associated with 3.5-fold higher risk of end-stage renal failure in HCM.•Diabetes is associated with 15% higher risk of heart failure in HCM.•Insulin-treated diabetes patients are at highest risk. Diabetes mellitus (DM) often coexists in elderly hypertrophic cardiomyopathy (HCM) patients; however, its impact on clinical outcomes is unclear. We compared clinical outcomes according to the presence of DM in a nationwide HCM cohort. In 9,883 HCM subjects (mean age 58.5 ± 13.1, men 71.7%), 1,327 (13.4%) had DM. During follow-up (mean 5.9 ± 2.5 years), end-stage renal disease (ESRD) progression, coronary events (myocardial infarction, coronary revascularization), heart failure (HF), cardiovascular mortality, and all-cause mortality occurred in 80 (0.8%), 365 (3.7%), 1,558 (15.8%), 354 (3.6%), and 877 (8.9%) subjects, respectively. DM HCM subjects had significantly higher risks of ESRD progression (HR 3.49, 95% CI 2.20–5.54) and HF (HR 1.15, 95% CI 1.01–1.32) compared to non-DM HCM subjects, independent of age, sex, ischemic heart disease, atrial fibrillation, and other comorbidities. There was a tendency for greater risk of ESRD progression, HF, and all-cause death in subjects with more advanced stage of DM (p-for-trend 
ISSN:0168-8227
1872-8227
DOI:10.1016/j.diabres.2022.109838